Vadim Pokrovskiy

Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study

Bonaventura Clotet, Judith Feinberg, Jan van Lunzen et al. · The Lancet · 2014 · 492 citations

Dolutegravir Versus Darunavir, Open-label Phase 3B, Treatment And Prevention +9

Comparison of Once-Daily Atazanavir With Efavirenz, Each in Combination With Fixed-Dose Zidovudine and Lamivudine, As Initial Therapy for Patients Infected With HIV

Kathleen Squires, Adriano Lazzarin, Jos M. Gatell et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 2004 · 299 citations

Body Fat and Other Metabolic Effects of Atazanavir and Efavirenz, Each Administered in Combination with Zidovudine plus Lamivudine, in Antiretroviral- Naive HIV-Infected Patients

Joseph G. Jemsek, Eduardo Arathoon, M. Arlotti et al. · Clinical Infectious Diseases · 2005 · 109 citations · Full text

Long-Term Efficacy and Safety of Atazanavir With Stavudine and Lamivudine in Patients Previously Treated With Nelfinavir or Atazanavir

Robin Wood, Praphan Phanuphak, Pedro Cahn et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 2004 · 102 citations

Long-term Efficacy, Pharmacotherapy, Antiviral Drug +16

Update on the epidemics of HIV and other sexually transmitted infections in the newly independent states of the former Soviet Union.

Karl L. Dehne, Vadim Pokrovskiy, Yuri V. Kobyshcha et al. · PubMed · 2000 · 68 citations

Former Soviet Union, Sexual Health, Virus Epidemiology +9